Skip to main content
Erschienen in: Endocrine 2/2016

16.10.2015 | Original Article

Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly

verfasst von: Ansgar Heck, Kyrre E. Emblem, Olivera Casar-Borota, Jens Bollerslev, Geir Ringstad

Erschienen in: Endocrine | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

In growth hormone (GH)-producing adenomas, T2-weighted MRI signal intensity is a marker for granulation pattern and response to somatostatin analogs (SSA). Prediction of treatment response is necessary for individualized treatment, and T2 intensity assessment might improve preoperative classification of somatotropinomas. The objectives of this study are (I) to explore the feasibility of quantitative T2-weighted MRI histogram analyses in newly diagnosed somatotroph adenomas and their relation to clinical and histological parameters and (II) to compare the quantitative method to conventional, visual assessment of T2 intensity. The study was a retrospective cohort study of 58 newly diagnosed patients. In 34 of these, response to primary SSA treatment after median 6 months was evaluated. Parameters from the T2 histogram analyses (T2 intensity ratio and T2 homogeneity ratio) were correlated to visually assessed T2 intensity (hypo-, iso-, hyperintense), baseline characteristics, response to SSA treatment, and histological granulation pattern (anti-Cam5.2). T2 intensity ratio was lowest in the hypointense tumors and highest in the hyperintense tumors (0.66 ± 0.10 vs. 1.07 ± 0.11; p < 0.001). T2 intensity at baseline correlated with reduction in GH (r = −0.67; p < 0.001) and IGF-1 (r = −0.36; p = 0.037) after primary SSA treatment (n = 34). The T2 homogeneity ratio correlated with adenoma size reduction (r = −0.45; p = 0.008). Sparsely granulated adenomas had a higher T2 intensity than densely or intermediately granulated adenomas. T2 histogram analyses are an applicable tool to assess T2 intensity in somatotroph adenomas. Quantitatively assessed T2 intensity ratio in GH-producing adenomas correlates with conventional assessment of T2 intensity, baseline characteristics, response to SSA treatment, and histological granulation pattern.
Literatur
1.
Zurück zum Zitat S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Acromegaly Consensus Group: guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009). doi:10.1210/jc.2008-2421 CrossRefPubMed S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Acromegaly Consensus Group: guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009). doi:10.​1210/​jc.​2008-2421 CrossRefPubMed
2.
Zurück zum Zitat A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K.Y. Ho, F.F. Casanueva, S. Melmed, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10(4), 243–248 (2014). doi:10.1038/nrendo.2014.21 CrossRefPubMed A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K.Y. Ho, F.F. Casanueva, S. Melmed, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10(4), 243–248 (2014). doi:10.​1038/​nrendo.​2014.​21 CrossRefPubMed
3.
Zurück zum Zitat L. Katznelson, E.R. Laws Jr, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014). doi:10.1210/jc.2014-2700 CrossRefPubMed L. Katznelson, E.R. Laws Jr, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014). doi:10.​1210/​jc.​2014-2700 CrossRefPubMed
4.
Zurück zum Zitat S.M. Carlsen, M. Lund-Johansen, T. Schreiner, S. Aanderud, O. Johannesen, J. Svartberg, J.G. Cooper, J.K. Hald, S.L. Fougner, J. Bollerslev, Preoperative Octreotide Treatment of Acromegaly study group: preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J. Clin. Endocrinol. Metab. 93(8), 2984–2990 (2008). doi:10.1210/jc.2008-0315 CrossRefPubMed S.M. Carlsen, M. Lund-Johansen, T. Schreiner, S. Aanderud, O. Johannesen, J. Svartberg, J.G. Cooper, J.K. Hald, S.L. Fougner, J. Bollerslev, Preoperative Octreotide Treatment of Acromegaly study group: preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J. Clin. Endocrinol. Metab. 93(8), 2984–2990 (2008). doi:10.​1210/​jc.​2008-0315 CrossRefPubMed
5.
Zurück zum Zitat Z.-G. Mao, Y.-H. Zhu, H.-L. Tang, D.-Y. Wang, J. Zhou, D.-S. He, H. Lan, B.-N. Luo, H.-J. Wang, Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur. J. Endocrinol. 162(4), 661–666 (2010). doi:10.1530/eje-09-0908 CrossRefPubMed Z.-G. Mao, Y.-H. Zhu, H.-L. Tang, D.-Y. Wang, J. Zhou, D.-S. He, H. Lan, B.-N. Luo, H.-J. Wang, Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur. J. Endocrinol. 162(4), 661–666 (2010). doi:10.​1530/​eje-09-0908 CrossRefPubMed
6.
Zurück zum Zitat M. Shen, X. Shou, Y. Wang, Z. Zhang, J. Wu, Y. Mao, S. Li, Y. Zhao, Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr. J. 57(12), 1035–1044 (2010)CrossRefPubMed M. Shen, X. Shou, Y. Wang, Z. Zhang, J. Wu, Y. Mao, S. Li, Y. Zhao, Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr. J. 57(12), 1035–1044 (2010)CrossRefPubMed
7.
Zurück zum Zitat S. Bacigaluppi, F. Gatto, P. Anania, N.L. Bragazzi, D.C. Rossi, G. Benvegnu, E. Nazzari, R. Spaziante, M. Giusti, D. Ferone, G. Zona, Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. Endocrine (2015). doi:10.1007/s12020-015-0619-5 PubMed S. Bacigaluppi, F. Gatto, P. Anania, N.L. Bragazzi, D.C. Rossi, G. Benvegnu, E. Nazzari, R. Spaziante, M. Giusti, D. Ferone, G. Zona, Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. Endocrine (2015). doi:10.​1007/​s12020-015-0619-5 PubMed
9.
Zurück zum Zitat S.L. Fougner, J. Bollerslev, J. Svartberg, M. Oksnes, J. Cooper, S.M. Carlsen, Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur. J. Endocrinol. 171(2), 229–235 (2014). doi:10.1530/EJE-14-0249 CrossRefPubMed S.L. Fougner, J. Bollerslev, J. Svartberg, M. Oksnes, J. Cooper, S.M. Carlsen, Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur. J. Endocrinol. 171(2), 229–235 (2014). doi:10.​1530/​EJE-14-0249 CrossRefPubMed
10.
Zurück zum Zitat S.M. Carlsen, J. Svartberg, T. Schreiner, S. Aanderud, O. Johannesen, S. Skeie, M. Lund-Johansen, S.L. Fougner, J. Bollerslev, Preoperative Octreotide Treatment of Acromegaly study group: six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin. Endocrinol. 74(6), 736–743 (2011). doi:10.1111/j.1365-2265.2011.03982.x CrossRef S.M. Carlsen, J. Svartberg, T. Schreiner, S. Aanderud, O. Johannesen, S. Skeie, M. Lund-Johansen, S.L. Fougner, J. Bollerslev, Preoperative Octreotide Treatment of Acromegaly study group: six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin. Endocrinol. 74(6), 736–743 (2011). doi:10.​1111/​j.​1365-2265.​2011.​03982.​x CrossRef
12.
Zurück zum Zitat S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, J. Bollerslev, Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76(1), 96–102 (2012). doi:10.1111/j.1365-2265.2011.04163.x CrossRef S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, J. Bollerslev, Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76(1), 96–102 (2012). doi:10.​1111/​j.​1365-2265.​2011.​04163.​x CrossRef
13.
Zurück zum Zitat A. Hagiwara, Y. Inoue, K. Wakasa, T. Haba, T. Tashiro, T. Miyamoto, Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2), 533–538 (2003). doi:10.1148/radiol.2282020695 CrossRefPubMed A. Hagiwara, Y. Inoue, K. Wakasa, T. Haba, T. Tashiro, T. Miyamoto, Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2), 533–538 (2003). doi:10.​1148/​radiol.​2282020695 CrossRefPubMed
14.
Zurück zum Zitat M. Puig-Domingo, E. Resmini, B. Gomez-Anson, J. Nicolau, M. Mora, E. Palomera, C. Marti, I. Halperin, S.M. Webb, Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J. Clin. Endocrinol. Metab. 95(11), 4973–4978 (2010). doi:10.1210/jc.2010-0573 CrossRefPubMed M. Puig-Domingo, E. Resmini, B. Gomez-Anson, J. Nicolau, M. Mora, E. Palomera, C. Marti, I. Halperin, S.M. Webb, Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J. Clin. Endocrinol. Metab. 95(11), 4973–4978 (2010). doi:10.​1210/​jc.​2010-0573 CrossRefPubMed
15.
Zurück zum Zitat A. Heck, G. Ringstad, S.L. Fougner, O. Casar-Borota, T. Nome, J. Ramm-Pettersen, J. Bollerslev, Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. 77(1), 72–78 (2012). doi:10.1111/j.1365-2265.2011.04286.x CrossRef A. Heck, G. Ringstad, S.L. Fougner, O. Casar-Borota, T. Nome, J. Ramm-Pettersen, J. Bollerslev, Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. 77(1), 72–78 (2012). doi:10.​1111/​j.​1365-2265.​2011.​04286.​x CrossRef
16.
Zurück zum Zitat I. Potorac, P. Petrossians, A.F. Daly, F. Schillo, C. Ben Slama, S. Nagi, M. Sahnoun, T. Brue, N. Girard, P. Chanson, G. Nasser, P. Caron, F. Bonneville, G. Raverot, V. Lapras, F. Cotton, B. Delemer, B. Higel, A. Boulin, S. Gaillard, F. Luca, B. Goichot, J.L. Dietemann, A. Beckers, J.F. Bonneville, Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr. Relat. Cancer 22(2), 169–177 (2015). doi:10.1530/ERC-14-0305 CrossRefPubMed I. Potorac, P. Petrossians, A.F. Daly, F. Schillo, C. Ben Slama, S. Nagi, M. Sahnoun, T. Brue, N. Girard, P. Chanson, G. Nasser, P. Caron, F. Bonneville, G. Raverot, V. Lapras, F. Cotton, B. Delemer, B. Higel, A. Boulin, S. Gaillard, F. Luca, B. Goichot, J.L. Dietemann, A. Beckers, J.F. Bonneville, Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr. Relat. Cancer 22(2), 169–177 (2015). doi:10.​1530/​ERC-14-0305 CrossRefPubMed
17.
Zurück zum Zitat K.E. Emblem, B. Nedregaard, T. Nome, P. Due-Tonnessen, J.K. Hald, D. Scheie, O.C. Borota, M. Cvancarova, A. Bjornerud, Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology 247(3), 808–817 (2008). doi:10.1148/radiol.2473070571 CrossRefPubMed K.E. Emblem, B. Nedregaard, T. Nome, P. Due-Tonnessen, J.K. Hald, D. Scheie, O.C. Borota, M. Cvancarova, A. Bjornerud, Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. Radiology 247(3), 808–817 (2008). doi:10.​1148/​radiol.​2473070571 CrossRefPubMed
18.
Zurück zum Zitat W.B. Pope, X.J. Qiao, H.J. Kim, A. Lai, P. Nghiemphu, X. Xue, B.M. Ellingson, D. Schiff, D. Aregawi, S. Cha, V.K. Puduvalli, J. Wu, W.K. Yung, G.S. Young, J. Vredenburgh, D. Barboriak, L.E. Abrey, T. Mikkelsen, R. Jain, N.A. Paleologos, P.L. Rn, M. Prados, J. Goldin, P.Y. Wen, T. Cloughesy, Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J. Neurooncol. 108(3), 491–498 (2012). doi:10.1007/s11060-012-0847-y CrossRefPubMedPubMedCentral W.B. Pope, X.J. Qiao, H.J. Kim, A. Lai, P. Nghiemphu, X. Xue, B.M. Ellingson, D. Schiff, D. Aregawi, S. Cha, V.K. Puduvalli, J. Wu, W.K. Yung, G.S. Young, J. Vredenburgh, D. Barboriak, L.E. Abrey, T. Mikkelsen, R. Jain, N.A. Paleologos, P.L. Rn, M. Prados, J. Goldin, P.Y. Wen, T. Cloughesy, Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J. Neurooncol. 108(3), 491–498 (2012). doi:10.​1007/​s11060-012-0847-y CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat S. Melmed, F.F. Casanueva, F. Cavagnini, P. Chanson, L. Frohman, A. Grossman, K. Ho, D. Kleinberg, S. Lamberts, E. Laws, G. Lombardi, M.L. Vance, K.V. Werder, J. Wass, A. Giustina, Acromegaly treatment consensus workshop participants: guidelines for acromegaly management. J. Clin. Endocrinol. Metab. 87(9), 4054–4058 (2002)CrossRefPubMed S. Melmed, F.F. Casanueva, F. Cavagnini, P. Chanson, L. Frohman, A. Grossman, K. Ho, D. Kleinberg, S. Lamberts, E. Laws, G. Lombardi, M.L. Vance, K.V. Werder, J. Wass, A. Giustina, Acromegaly treatment consensus workshop participants: guidelines for acromegaly management. J. Clin. Endocrinol. Metab. 87(9), 4054–4058 (2002)CrossRefPubMed
20.
Zurück zum Zitat D. Ferone, W.W. de Herder, R. Pivonello, J.M. Kros, P.M. van Koetsveld, T. de Jong, F. Minuto, A. Colao, S.W.J. Lamberts, L.J. Hofland, Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J. Clin. Endocrinol. Metab. 93(4), 1412–1417 (2008). doi:10.1210/jc.2007-1358 CrossRefPubMed D. Ferone, W.W. de Herder, R. Pivonello, J.M. Kros, P.M. van Koetsveld, T. de Jong, F. Minuto, A. Colao, S.W.J. Lamberts, L.J. Hofland, Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J. Clin. Endocrinol. Metab. 93(4), 1412–1417 (2008). doi:10.​1210/​jc.​2007-1358 CrossRefPubMed
21.
Zurück zum Zitat P.J. Caron, J.S. Bevan, S. Petersenn, D. Flanagan, A. Tabarin, G. Prevost, P. Maisonobe, A. Clermont, P. Investigators, Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. 99(4), 1282–1290 (2014). doi:10.1210/jc.2013-3318 CrossRefPubMedPubMedCentral P.J. Caron, J.S. Bevan, S. Petersenn, D. Flanagan, A. Tabarin, G. Prevost, P. Maisonobe, A. Clermont, P. Investigators, Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. 99(4), 1282–1290 (2014). doi:10.​1210/​jc.​2013-3318 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat A. Obari, T. Sano, K. Ohyama, E. Kudo, Z.R. Qian, A. Yoneda, N. Rayhan, M. Mustafizur Rahman, S. Yamada, Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82–91 (2008). doi:10.1007/s12022-008-9029-z CrossRefPubMed A. Obari, T. Sano, K. Ohyama, E. Kudo, Z.R. Qian, A. Yoneda, N. Rayhan, M. Mustafizur Rahman, S. Yamada, Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82–91 (2008). doi:10.​1007/​s12022-008-9029-z CrossRefPubMed
24.
Zurück zum Zitat A.L. Edal, K. Skjodt, H.J. Nepper-Rasmussen, SIPAP–a new MR classification for pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior. Acta Radiol. 38(1), 30–36 (1997)CrossRefPubMed A.L. Edal, K. Skjodt, H.J. Nepper-Rasmussen, SIPAP–a new MR classification for pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior. Acta Radiol. 38(1), 30–36 (1997)CrossRefPubMed
25.
Zurück zum Zitat E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610–617 (1993); discussion 617–618 CrossRefPubMed E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610–617 (1993); discussion 617–618 CrossRefPubMed
28.
Zurück zum Zitat N.C. Olarescu, A. Heck, K. Godang, T. Ueland, J. Bollerslev, The metabolic risk in newly diagnosed patients with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology (2015). doi:10.1159/000371818 PubMed N.C. Olarescu, A. Heck, K. Godang, T. Ueland, J. Bollerslev, The metabolic risk in newly diagnosed patients with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology (2015). doi:10.​1159/​000371818 PubMed
29.
Zurück zum Zitat S. Bhayana, G.L. Booth, S.L. Asa, K. Kovacs, S. Ezzat, The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J. Clin. Endocrinol. Metab. 90(11), 6290–6295 (2005). doi:10.1210/jc.2005-0998 CrossRefPubMed S. Bhayana, G.L. Booth, S.L. Asa, K. Kovacs, S. Ezzat, The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J. Clin. Endocrinol. Metab. 90(11), 6290–6295 (2005). doi:10.​1210/​jc.​2005-0998 CrossRefPubMed
30.
Zurück zum Zitat K. Kiseljak-Vassiliades, N.E. Carlson, M.T. Borges, B.K. Kleinschmidt-DeMasters, K.O. Lillehei, J.M. Kerr, M.E. Wierman, Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1), 231–241 (2015). doi:10.1007/s12020-014-0383-y CrossRefPubMed K. Kiseljak-Vassiliades, N.E. Carlson, M.T. Borges, B.K. Kleinschmidt-DeMasters, K.O. Lillehei, J.M. Kerr, M.E. Wierman, Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1), 231–241 (2015). doi:10.​1007/​s12020-014-0383-y CrossRefPubMed
31.
Zurück zum Zitat Y. Bakhtiar, H. Hirano, K. Arita, S. Yunoue, S. Fujio, A. Tominaga, T. Sakoguchi, K. Sugiyama, K. Kurisu, J. Yasufuku-Takano, K. Takano, Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 163(4), 531–539 (2010). doi:10.1530/EJE-10-0586 CrossRefPubMed Y. Bakhtiar, H. Hirano, K. Arita, S. Yunoue, S. Fujio, A. Tominaga, T. Sakoguchi, K. Sugiyama, K. Kurisu, J. Yasufuku-Takano, K. Takano, Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 163(4), 531–539 (2010). doi:10.​1530/​EJE-10-0586 CrossRefPubMed
32.
Zurück zum Zitat S. Yamada, T. Aiba, T. Sano, K. Kovacs, Y. Shishiba, S. Sawano, K. Takada, Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1), 20–27 (1993)CrossRefPubMed S. Yamada, T. Aiba, T. Sano, K. Kovacs, Y. Shishiba, S. Sawano, K. Takada, Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1), 20–27 (1993)CrossRefPubMed
33.
Zurück zum Zitat P. Boulby, T2: the transverse relaxation time, in Quantitative MRI of the brain—measuring changes caused by disease, vol. 1, ed. by P. Tofts (Wiley, Chichester, 2004), pp. 143–201 P. Boulby, T2: the transverse relaxation time, in Quantitative MRI of the brain—measuring changes caused by disease, vol. 1, ed. by P. Tofts (Wiley, Chichester, 2004), pp. 143–201
34.
Zurück zum Zitat A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, G. Acromegaly Consensus, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141–3148 (2010). doi:10.1210/jc.2009-2670 CrossRefPubMed A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, G. Acromegaly Consensus, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141–3148 (2010). doi:10.​1210/​jc.​2009-2670 CrossRefPubMed
Metadaten
Titel
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly
verfasst von
Ansgar Heck
Kyrre E. Emblem
Olivera Casar-Borota
Jens Bollerslev
Geir Ringstad
Publikationsdatum
16.10.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0766-8

Weitere Artikel der Ausgabe 2/2016

Endocrine 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.